Drug Discovery & Development
Mouse Model of Diabetes
Inventors: Nader Sheibani-Karkhaneh, Christine Sorenson
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a line of TSP1 negative mice that provide an animal model for diabetic retinopathy.
There is a lack of effective and non-destructive treatments for diabetic retinopathy, a major cause of blindness in the United States. Thrombospondin1 (TSP1), a matricellular protein that inhibits angiogenesis in vivo and is essential for proper retinal vascular development, is dramatically down-regulated in ocular samples from diabetic rats.
Based on this observation, UW-Madison researchers developed a line of TSP1 negative mice that provide an animal model for diabetic retinopathy. They crossed Akita/+ mice that develop diabetes between three and four weeks of age with TSP1 -/- mice. The resulting Akita/+ TSP1 -/- mice develop diabetes-associated vasculopathies of greater severity and at a much earlier stage of diabetes than the Akita/+ mice. These mice also show a dramatic increase in acellular capillaries and saccular microaneurysms, which are some of the early signs of diabetic retinopathy.
- Testing the effects of new compounds for treating diabetic retinopathy
- Studying the many vasculopathies associated with diabetes
- Mice become useful models by six months of age, avoiding issues with drug testing in aged mice
- Mice may develop proliferative retinopathy (the final stage of diabetic retinopathy), which has never been demonstrated in rodent models of diabetes
For More Information About the Inventors